About US
Contact us
-
Amgen falls short in Epogen patent appeal but Pfizer stumble delays competitionWith a federal appeals decision handed down this week, Amgen has come up short in a legal attempt to defend blockbuster anemia med Epogen from a Pfizer biosim. However, the company’s loss in appeals d2017/8/22
-
CVS, Walgreens and PBMs worked together to gouge consumers, lawsuits claimEven as the generic drug industry works through challenging pricing dynamics, new lawsuits say consumers aren’t realizing all of the benefits from the low prices dragging on the industry’s players. I2017/8/22
-
New Hampshire, 'ground zero' of addiction epidemic, sues Purdue Pharma for overhyping opioidsA number of states fighting opioid addiction have sued top drugmakers, but now New Hampshire has set its sights on a single company. The state filed a civillawsuitagainst Purdue Pharma, maker of OxyCo2017/8/21
-
Expect a Big Pharma ripple effect from United Therapeutics' $210M settlement talks with feds: expertTop pharma players have disclosed federal investigations into their patient assistance contributions, but only United Therapeutics has said it's working ona settlement. That company’s set-aside of $212017/8/21
-
England’s chief medical officer calls for better access to genetic testingEngland’s chief medical officer professor Dame Sally Davies has highlighted the need for routine access to genetic testing to improve diagnosis and treatment of cancer in the UK. Davies urged the cli2017/8/4
-
Novartis and IBM Watson to optimise cancer care and patient outcomesNovartis has partnered with IBM Watson Health on an outcome-based initiative for patients with advanced breast cancer. The collaboration will involve research on a cognitive solution that uses real-w2017/8/4
-
Puma's Nerlynx unleashed to fight HER2+ breast cancer with 'best case' labelPuma Biotechnology grabbed its FDA approval for neratinib, the kinase inhibitor it’s been developing for HER2-positive breast cancer, but that doesn’t mean the newly dubbed Nerlynx will be roaring ont2017/8/3
-
Roche's hold on Avastin, Herceptin sales loosens as FDA panel backs Amgen and Mylan biosimsRoche took a blockbuster double hit Thursday as the FDA’s Oncologic Drugs Advisory Committee recommended an Amgen biosimilar to Avastin in the morning, and then a Mylan biosim to Herceptin in the afte2017/8/3
-
Racing toward a historic CAR-T approval, Novartis wins unanimous FDA panel backingAll eyes in the drug industry turned to the FDA’s Oncologic Drugs Advisory Committee meeting Wednesday, where Novartis won crucial backing for its lead CAR-T drug. By a 10-0 vote, FDA panel experts e2017/8/2
-
Unable to head off the FDA, Ocular Therapeutix gets second CRL for eye drugManufacturing has for the second time stepped on Ocular Therapeutix’s chance of an FDA approval for its new drug for pain following eye surgery. The Bedford, Massachusetts, biotech todaysaidthe FDA h2017/8/2